Skip to Content

Crenolanib Approval Status

FDA Approved: No
Generic name: crenolanib
Company: Arog Pharmaceuticals, Inc.
Treatment for: Acute Myeloid Leukemia, Gastrointestinal Stromal Tumor

Crenolanib is benzimidazole type I kinase inhibitor in development for the treatment for multiple cancers, including acute myeloid leukemia (AML) and gastrointestinal stromal tumors (GIST).

Development Status and FDA Approval Process for crenolanib

DateArticle
Nov 16, 2016Arog Pharmaceuticals Receives FDA Fast Track Designation for Crenolanib for Advanced Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide